David Kendall named Zealand Pharma CMO
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated